Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 19;14(1):5038.
doi: 10.1038/s41467-023-39786-7.

Challenges in developing Geroscience trials

Yves Rolland  1   2 , Felipe Sierra  3 , Luigi Ferrucci  4 , Nir Barzilai  5 , Rafael De Cabo  6 , Joan Mannick  7 , Anthony Oliva  8 , William Evans  9 , Davide Angioni  10 , Philipe De Souto Barreto  10   11 , Jeremy Raffin  10   11 , Bruno Vellas  10   11 , James L Kirkland  12 ; G.C.T-TF group
Collaborators, Affiliations
Review

Challenges in developing Geroscience trials

Yves Rolland et al. Nat Commun. .

Abstract

Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both selecting interventions and predicting or monitoring clinical responses ("Gerodiagnostics"). This article reports the main results of a Task Force of experts in Geroscience.

PubMed Disclaimer

Conflict of interest statement

The views expressed in the manuscript the personal views of the authors and may not be understood as being made on behalf of organizations with which the authors are affiliated. Y.R. reports support from CHU Toulouse, University Paul Sabatier, INSERM CERPOP1295 (Employee), to be a shareholder of SARQOL SPRL, a spin-off of the University of Liege, consultancy fees from Longeveron, Biophytis, and honoraria for lectures for Pfizer. N.B. reported grants from the National Institutes of Health (P01AG021654) (N.B.), the Nathan Shock Center of Excellence for the basic Biology of Aging (P30AG038072) (N.B.), the Einstein-Paul Glenn Foundation for Medical Research Center for the Biology of Human Aging (N.B.), and taking part to advisory boards of Longevity Biotceh Association and Health Longevity Medical Society. A.O. reports support from Longeveron (Employee) and grants from National Institute on Aging (NIA)/National Institutes of Health (NIH) and Alzheimer’s Association. WE reports grants from the National Institutes of Health (1R01AG059416, R01CA246695, 5R01AG055443-02, 1R01AG065265, UCB 20210962, UCB 20210962, R01 AG074956-01, 1U01CA271277-01, 1R37CA258761-01A1) and consulting fees from BioAge Labs. B.V. reports support from CHU Toulouse, University Paul Sabatier and INSERM CERPOP1295 (employee), grant from Pfizer, Pierre Fabre. J.K. reports grants from US NIH paid to Mayo Clinic (grant R01AG 072301, P01AG 062413, R37AG 13925, R33AG 61456, R01AG 64165, R01AG 55529, R01DK 120292, R01DK 119167, R01HL 141819, R01AG 68048, UH3AG 56933 U54AG 075941, UG3CA 268103, R25AG 073119, R01AG 61414) and the Alzheimer’s Association (PTC REG-20-651687), consulting fees from Oklahoma Medical Research Foundation Scientific Advisory Board, and Henry Ford Health System, support for attending meetings (travel expense reimbursement) from AFAR, FASEB meeting, American Thoracic Society 2022 International Conference, Association for Research in Vision and Ophthalmology, Oriel College (Oxford University), 12th International Conference on Frailty and Sarcopenia Research (Boston), University of California (San Diego), Harvard University, 2nd Euro Geroscience Conference (Toulouse), University of North Carolina, University of Kansas Medical Center, Steadman Clinic (Vail), Gerontological Society of American, Longevity Medicine Society, patents (planned, issued, or pending/rights held by Mayo Clinic), and leadership at the American Federation for Aging Research board. Other authors (F.S., L.F., R.d.C., J.M., D.A., P.d.S.B., and J.R.) report no conflicts of interest.

References

    1. Franceschi C, et al. The continuum of aging and age-related diseases: common mechanisms but different rates. Front Med. 2018;5:61. - PMC - PubMed
    1. Harper S. Economic and social implications of aging societies. Science. 2014;346:587–591. - PubMed
    1. Seals DR, Justice JN, LaRocca TJ. Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity. J. Physiol. (Lond.). 2016;594:2001–2024. - PMC - PubMed
    1. Kulkarni AS, et al. Geroscience-guided repurposing of FDA-approved drugs to target aging: a proposed process and prioritization. Aging Cell. 2022;21:e13596. - PMC - PubMed
    1. Wyles SP, Tchkonia T, Kirkland JL. Targeting cellular senescence for age-related diseases: path to clinical translation. Plast. Reconstr. Surg. 2022;150:20S–26S. - PMC - PubMed

Publication types